Atossa Therapeutics, Inc. (ATOS) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Atossa Therapeutics (ATOS) by buying shares or fractional shares at any major US broker. Atossa is a clinical-stage biopharmaceutical company developing treatments for breast cancer, led by its investigational oral drug (Z)-endoxifen for ER+/HER2- disease and related conditions. The thesis is a bet that (Z)-endoxifen advances through trials such as the EVANGELINE Phase 2 study toward an eventual regulatory filing. It is important to understand that Atossa is pre-revenue with no approved product, funds itself by burning cash and issuing stock, and its value hinges on binary clinical and regulatory outcomes. That makes ATOS a highly speculative, small-cap biotech position rather than a stable earnings-based investment.
ATOS stock price
As of 2026-07-14, Atossa Therapeutics, Inc. (ATOS) last closed at $2.28, down 83.8% over the past year. Over the past 52 weeks it has traded between $1.75 and $17.70.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Atossa Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Atossa Therapeutics, Inc. (ATOS) do?
Atossa Therapeutics, Inc. (ATOS) is a clinical-stage biopharmaceutical company focused on breast cancer. Its lead investigational asset is (Z)-endoxifen, an oral active metabolite of tamoxifen being studied for ER+/HER2- breast cancer and for reducing mammographic breast density. Key programs include the EVANGELINE Phase 2 trial evaluating (Z)-endoxifen with ovarian function suppression as a neoadjuvant therapy in premenopausal patients, which the company streamlined in late 2025 to prioritize near-term, NDA-enabling activities in 2026, and the KARISMA endoxifen study, whose results in healthy premenopausal women were published in 2026. Atossa has no approved products and generates no meaningful product revenue.
As a clinical-stage developer, Atossa funds operations through cash reserves and equity issuance rather than sales. The company reported a going concern warning alongside its early-2026 results, reflecting recurring losses and limited cash resources, and it carried out a 15-for-1 reverse stock split in February 2026 to regain Nasdaq minimum-bid-price compliance. Its future depends on clinical data readouts, regulatory decisions, and its ability to keep financing a cash-consuming pipeline. Investors should treat ATOS as a binary, single-asset-concentrated biotech story where outcomes can swing sharply on trial and regulatory news.
What's driving Atossa Therapeutics, Inc. (ATOS)?
1. (Z)-endoxifen as the central value driver
Atossa's investment case rests overwhelmingly on (Z)-endoxifen, an oral endocrine therapy candidate positioned for ER+/HER2- breast cancer and for reducing mammographic breast density. Because it is a single lead asset, the company's prospects rise or fall largely with this one program. Positive pharmacodynamic and clinical signals to date have kept the story alive, but the drug remains investigational with no guarantee of eventual approval. Any investor thesis for ATOS is effectively a concentrated wager on this molecule advancing through trials and regulatory review.
2. EVANGELINE and pipeline progression
The EVANGELINE Phase 2 trial studies (Z)-endoxifen combined with ovarian function suppression as a neoadjuvant therapy in premenopausal ER+/HER2- patients. In late 2025 Atossa streamlined the study toward a non-registrational design intended to accelerate readouts and reduce future study costs while prioritizing NDA-enabling activities in 2026. Reaching those milestones on schedule would be a meaningful catalyst, but trial timelines in oncology are long, and amended or non-registrational designs can still require substantial additional work before any filing.
3. Broader indications and supporting data
Beyond metastatic and neoadjuvant breast cancer, Atossa has explored (Z)-endoxifen and endoxifen in areas such as breast density reduction and risk reduction. The KARISMA endoxifen study, published in 2026, reported reductions in mammographic breast density in healthy premenopausal women, which the company frames as supportive of development in women at elevated risk. These adjacent uses could broaden the addressable opportunity if validated, though each would require its own dedicated trials, regulatory pathway, and funding.
4. Financing capacity and dilution management
As a pre-revenue biotech, Atossa's ability to keep operating depends on access to capital. The company remains debt-free and has used at-the-market equity programs to raise funds, but issuing shares dilutes existing holders, and it disclosed a going concern warning in early 2026. Prudent cost management, such as streamlining EVANGELINE, extends runway, yet the underlying reality is that continued clinical progress will likely require further capital raises that can pressure the share count and price.
What are the risks to Atossa Therapeutics, Inc. (ATOS)?
ATOS carries the full spectrum of clinical-stage biotech risk. Its value is binary and single-asset concentrated: disappointing data or a regulatory setback for (Z)-endoxifen could sharply reduce the equity's worth, since there is no approved product or revenue to fall back on. Clinical trials can fail at any stage, and even positive Phase 2 signals do not guarantee approval. The company burns cash to fund operations and disclosed substantial doubt about its ability to continue as a going concern, meaning it must repeatedly raise money. That financing is typically done by issuing stock, diluting shareholders, and the company executed a 15-for-1 reverse split in 2026 to maintain Nasdaq listing compliance. As a small-cap, shares can be volatile and thinly traded. Investors should size any position accordingly and treat total loss as a realistic outcome.
How is Atossa Therapeutics, Inc. (ATOS) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Atossa Therapeutics, Inc.'s investor relations page or your broker.
- Product revenue: None. Atossa is pre-revenue with no approved product; it earns no meaningful product sales.
- Cash position: Held cash and equivalents in the low tens of millions of dollars as of early 2026; the company is debt-free but disclosed a going concern warning.
- Cash runway: Limited. Quarterly cash burn is in the high single-digit millions, implying only a few quarters of runway before additional financing is likely needed.
- Lead program: (Z)-endoxifen for ER+/HER2- breast cancer, with the EVANGELINE Phase 2 trial and supporting studies still in clinical development.
- Market cap: Small-cap. Classified as a smaller reporting company; valuation reflects speculative pipeline potential, not earnings.
- Analyst view: Coverage is thin and speculative given the clinical-stage profile; any targets hinge on trial outcomes rather than financial fundamentals.
These figures are qualitative and directional, not exact. A clinical-stage biotech like Atossa is valued on the perceived potential of its pipeline rather than on current earnings, because it has no product revenue and runs at a loss by design. The metric that matters most is cash runway: how long existing funds can sustain trials before the company must raise more capital, typically by issuing shares. Always confirm the latest reported cash, burn rate, and share count in Atossa's most recent SEC filings before making any decision.
Who competes with Atossa Therapeutics, Inc. (ATOS)?
Clinical-stage breast-cancer developers
Other small and mid-cap biotechs advancing endocrine or targeted therapies for ER+ breast cancer compete with Atossa for trial patients, clinical validation, and investor capital. Like Atossa, many are pre-revenue and valued on pipeline potential, so they share the same binary, data-driven risk profile.
Large oncology pharmaceutical companies
Established drugmakers with approved breast-cancer franchises and deep research budgets set the standard of care that any new therapy must improve upon or complement. Their scale, marketed products, and resources make them the eventual benchmark, partner, or acquirer for smaller developers such as Atossa.
SERD and endocrine-therapy peers
Companies developing selective estrogen receptor degraders, modulators, and other endocrine therapies target overlapping ER+ patient populations. These programs represent both scientific competition and the comparative context in which (Z)-endoxifen's differentiation and tolerability profile will ultimately be judged.
How to invest in Atossa Therapeutics, Inc. (ATOS)
There are three common ways to get ATOS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ATOS sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where ATOS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Atossa Therapeutics, Inc. (ATOS)
Atossa is a speculative, pre-revenue clinical-stage biotech whose value rests almost entirely on whether (Z)-endoxifen succeeds in trials and eventual regulatory review. There is no profit, revenue, or approved product, and cash burn plus dilution are ongoing. Suitable only for high-risk, long-horizon capital you can afford to lose.
Build a basket around ATOS with Walnut
Use Atossa Therapeutics, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ATOS a good stock to buy right now?
+
That depends entirely on your risk tolerance. ATOS is a speculative, pre-revenue clinical-stage biotech whose value hinges on binary trial and regulatory outcomes for a single lead drug. It could rise sharply on positive data or fall to near zero on a setback. This is not investment advice; only high-risk capital you can afford to lose is appropriate.
What is (Z)-endoxifen?
+
(Z)-endoxifen is Atossa's lead investigational drug, an oral active metabolite of the breast-cancer medicine tamoxifen. Atossa is studying it for ER+/HER2- breast cancer and for reducing mammographic breast density. It is not approved by regulators and remains in clinical trials, so its safety and efficacy are still being evaluated.
Why does Atossa have no revenue?
+
Atossa is a clinical-stage company with no approved product to sell, so it generates no meaningful product revenue. Instead it spends money running clinical trials and research, funding those costs from cash reserves and by issuing stock. Revenue would only begin if a drug is approved and commercialized, which is uncertain and years away.
What is the EVANGELINE trial?
+
EVANGELINE is Atossa's Phase 2 trial evaluating (Z)-endoxifen combined with ovarian function suppression as a neoadjuvant therapy in premenopausal ER+/HER2- breast cancer patients. In late 2025 the company streamlined the study to prioritize near-term, NDA-enabling activities in 2026 and reduce future costs. Its readouts are a key catalyst to watch.
Is Atossa Therapeutics profitable?
+
No. Atossa is not profitable and operates at a net loss by design, as it invests in clinical development without any product sales. Losses and negative operating cash flow are expected for a clinical-stage biotech and are likely to continue until, and only if, a product is approved and successfully commercialized.
Can I get exposure to ATOS through an ETF instead?
+
Possibly, but only in small amounts. As a micro to small-cap biotech, ATOS may appear at a tiny weight in broad small-cap or biotech index ETFs rather than as a major holding. An ETF spreads risk across many companies, which dilutes both the upside and the single-stock risk of owning ATOS directly.
What are the main risks of investing in ATOS?
+
The main risks are clinical and regulatory failure of (Z)-endoxifen, ongoing cash burn with a disclosed going concern, dilution from repeated stock issuance, single-asset concentration, and small-cap volatility with thin trading. Because there is no revenue or approved product, a total loss is a realistic outcome. ATOS is only suitable for speculative, long-horizon capital.
What should I watch to track Atossa's progress?
+
Focus on clinical data readouts for (Z)-endoxifen, including EVANGELINE and related studies, plus any regulatory interactions or NDA-enabling milestones. Also monitor cash position, quarterly burn rate, and share count in each SEC filing, since financing capacity is central to a pre-revenue biotech's survival and to potential dilution.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Atossa Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.